AZ1495

Overview

AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 ( IRAK4 ) inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC 50 values of 0.005 μM and 0.023 μM, respectively. AZ1495 has IRAK4 inhibition with a K d value of 0.0007 μM. AZ1495 can be used for the research of diffuse large B-cell lymphoma (DLBCL).

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > IRAK

Product Information

• Catalog No.: HY-111101
• CAS No.: 2196204-23-4
• Molecular Formula: C21H31N5O2
• Molecular Weight: 385.50
• Purity: 98.07%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 1 mg/mL (2.59 mM); Clear solution
• Availability: In-stock

Source

Original product source